Bicycle Therapeutics (BCYC) Income towards Parent Company (2018 - 2026)

Bicycle Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$60.8 million for Q1 2026.

• Quarterly Income towards Parent Company changed 0.12% year-over-year to -$60.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 102.73% YoY) and the FY2025 annual result came in at $5.6 million, up 103.34% from the prior year.
• Income towards Parent Company was -$60.8 million for Q1 2026 at Bicycle Therapeutics, down from $204.5 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $204.5 million in Q4 2025 and bottomed at -$79.0 million in Q2 2025.
• A 5-year average of -$19.8 million and a median of -$39.8 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 517.79% — and 2024, when it sank 138.72%.
• Bicycle Therapeutics' Income towards Parent Company stood at -$32.0 million in 2022, then soared by 517.79% to $133.8 million in 2023, then sank by 138.72% to -$51.8 million in 2024, then surged by 494.55% to $204.5 million in 2025, then sank by 129.75% to -$60.8 million in 2026.
• Business Quant data shows BCYC's Income towards Parent Company at -$60.8 million in Q1 2026, $204.5 million in Q4 2025, and -$59.1 million in Q3 2025.